Abstracts tagged "psoriasis"

Abstract Number: 0053 • ACR Convergence 2021
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Darshini Ganatra³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of patients with psoriasis. Thus, early diagnosis of this subgroup is crucial to…
Abstract Number: 0054 • ACR Convergence 2021
TCR Immune Profiling of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: CD8+ and CD4+ T cell subsets have been implicated in the pathogenesis of psoriatic disease. Here, we explore the T-cell repertoire in psoriatic disease…
Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Jana Ziob¹, Charlotte Behning¹, Peter Brossart², Thomas Bieber¹, Dagmar Wilsmann-Theis³ and Valentin Schäfer⁴, ¹University Hospital Bonn, Bonn, Germany, ²Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…
Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
yongdong Zhao¹, Erin Sullivan², Mary Beth Son³ and Timothy Beukelman⁴, ¹University of Washington, Redmond, WA, ²Seattle Children's Research Institute, Seattle, WA, ³Boston Children's Hospital, Brookline, MA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…
Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Piotr Wiland¹, Andrew Blauvelt², Lena Lemke³, Oliver von Richter⁴, Alison Balfour⁴, Fabricio Furlan⁴ and Norman Gaylis⁵, ¹Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ²Oregon Medical Research Center, Portland, ³Hexal AG (A Sandoz company), Holzkirchen,Germany, Holzkirchen, Germany, ⁴Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁵Arthritis and Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…
Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Julia Manasson¹, Matthew Stapylton², Rhina Medina¹, Rochelle Castillo³, Parvathy Vasudevanpillai Girija¹, Adriana Heguy¹, Carles Ubeda⁴, Mid-Atlantic Twin Registry (MATR)⁵, Jose Clemente² and Jose Scher¹, ¹New York University School of Medicine, New York, NY, ²Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ³NYU Langone Health, New York, NY, ⁴La Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain; CIBERESP, Madrid, Spain, ⁵Virginia Commonwealth University, Richmond, VA
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…
Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Megan Meier¹, Jessica Walsh² and Shaobo Pei³, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
Abstract Number: 1784 • ACR Convergence 2021
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
Alexis Ogdie-Beatty¹, Bruce Strober², Mark Lebwohl³, Angel Cronin⁴, Tin-chi Lin⁴, Hyung-Joo Kang⁴, Nicole Middaugh⁴, Jacqueline O’Brien⁴, Shauna Jardon⁵, Sven Richter⁶, Yuri Klyachkin⁷ and Philip Mease⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Yale University, New Haven, CT, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴CorEvitas, LLC, Waltham, MA, ⁵Amgen Inc., Gilbert, AZ, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen Inc., Lexington, KY, ⁸Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…
Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Shashank Cheemalavagu¹, Yuxuan Jin² and Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 104 • 2019 ACR/ARP Annual Meeting
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Santosh Vishwakarma¹, Gurulingappa Hallur ¹, Himanshu Agrawal ¹, Sharad Singh ¹, Annasaheb Kalange ¹, Seema Chikkur Gangadhar ¹, Shuvranshu PraharaJ ¹, Nafees Ahmad Quresh ¹, Srikanth Kanagal Gopinath ¹, Krishnakumar V ¹, Sameer Mahmood ¹, Rudresh G ¹, Mohd Zainuddin ¹, Rajendra Kristam ¹, Ishtiyaque Ahmad ¹, Ramachandraiah Gosu ¹, Purra Buchi Reddy ¹, N V S K Rao ¹, Saloni Mehra ², Jeyaraj D A ¹, Takeshi Yura ¹, Saravanakumar dhakshinamoorthy ¹, Sriram Rajagopal ¹, Dhanalakshmi Sivanandhan ³ and Sridharan Rajagopal ³, ¹Jubilant Biosys, Bangalore, India, ²Jubilant Chemsys, Noida, India, ³Jubilant Therapeutics, Bangalore, India
Background/Purpose: Citrullination of proteins is catalyzed by a family of enzymes called the peptidylarginine deiminases (PADs). While the citrullinated proteins may have physiological roles in differentiation,…
Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Diamant Thaçi ¹, Kristian Reich ², Jo Lydie Lambert ³, Lars Iversen ⁴, Andrea Peserico ⁵, Ignasi Pau-Charles ⁶, Andrew Blauvelt⁷ and Christopher Griffiths ⁸, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, Lübeck, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ³Department of Dermatology, Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁴Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁵Clinica Dermatologica, Department of Medicine-DIMED University of Padua, Padua, Italy, Padua, Italy, ⁶Almirall R&D, Barcelona, Spain, Barcelona, Spain, ⁷Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ⁸Centre for Dermatology Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].